BioSpace News Archive

Alkermes plc (Nasdaq: ALKS) (the Company) today announced that it has filed an investor presentation with the U.S. Securities and Exchange Commission (SEC) in connection with the Company’s upcoming 2023 annual general meeting of shareholders (the Annual Meeting), which is scheduled to be held on June 29, 2023.

Kazia Therapeutics Limited is pleased to announce that it is supporting the University of Sydney on a molecularly-guided phase II clinical study to examine paxalisib in adult patients with recurrent/progressive isocitrate dehydrogenase (IDH) mutant grade 2 and 3 glioma.

Bristol Myers Squibb (NYSE: BMY) will announce results for the second quarter of 2023 on Thursday, July 27, 2023.

The Institute for Protein Innovation (IPI) , today announced a strategic partnership to accelerate biomedical research and therapeutic development through the discovery, development, and distribution of recombinant antibodies and other protein and DNA reagents.

Repare Therapeutics Inc. today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time in Dana Point, California.

Aviko Radiopharmaceuticals and Neutron Therapeutics today announced the formation of a strategic partnership to advance BNCT to treat cancer.

Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases.

Bausch + Lomb Corporation today announced that researchers will present the results of 11 scientific poster presentations involving the company’s consumer, vision care and pharmaceutical products during the American Optometric Association (AOA) Optometry’s Meeting e-posters Virtual Event, which is taking place from June 13-14, 2023.

Inversago Pharma to Present Data from Phase 1b Trial of INV-202, a Peripheral CB1r Blocker for Metabolic Syndrome, at the 83rd American Diabetes Association Scientific Sessions.

Escient Pharmaceuticals today announced the presentation of preclinical data in multiple models of mast cell degranulation related to the company’s EP262 development program at the European Academy of Allergy and Clinical Immunology annual meeting being held in Hamburg, Germany, June 9-11, 2023.